VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

Rationale for mTOR Inhibition in pNETs

Insights From: Matthews H. Kulke, MD, Harvard Medical School; Jonathan R. Strosberg, MD, Moffitt Cancer Center; James C. Yao, MD, University of Texas MD Anderson Cancer Center
Published: Saturday, Dec 19, 2015


Genomic studies have shown that select individuals with pancreatic neuroendocrine tumors (pNETs) express mutations in the mTOR pathway. Building upon this, results from the phase III, placebo-controlled RADIANT-3 study demonstrated improvements in progression-free survival in patients with advanced pNETs who received everolimus, an mTOR inhibitor, compared with those who received best supportive care.

In the study, median progression-free survival was 11 months in the everolimus arm versus 4.6 months in the placebo arm, says James C. Yao, MD. Other studies have suggested that patients who do not have mutations in these pathways can still benefit from treatment with mTOR inhibitors, states Matthew H. Kulke, MD.

Selection of which targeted agents to use in patients with pNETs depends on the safety profile of the medications, comments Yao. For example, everolimus may be favored over sunitinib, a tyrosine kinase inhibitor, in individuals with hypertension or history of cardiovascular disease and heart failure, while sunitinib may be preferred in patients with uncontrolled diabetes or oxygen-dependent COPD.

Everolimus may also be preferred in the setting of functional tumors because data indicate that everolimus delays disease progression and reduces tumor-secreted hormones from pNETs. The data for gastrin and glucagon are quite strong in this setting, notes Yao, and other data suggest that everolimus may be effective in controlling malignant hypoglycemia among patients with metastatic insulinomas.
Slider Left
Slider Right


Genomic studies have shown that select individuals with pancreatic neuroendocrine tumors (pNETs) express mutations in the mTOR pathway. Building upon this, results from the phase III, placebo-controlled RADIANT-3 study demonstrated improvements in progression-free survival in patients with advanced pNETs who received everolimus, an mTOR inhibitor, compared with those who received best supportive care.

In the study, median progression-free survival was 11 months in the everolimus arm versus 4.6 months in the placebo arm, says James C. Yao, MD. Other studies have suggested that patients who do not have mutations in these pathways can still benefit from treatment with mTOR inhibitors, states Matthew H. Kulke, MD.

Selection of which targeted agents to use in patients with pNETs depends on the safety profile of the medications, comments Yao. For example, everolimus may be favored over sunitinib, a tyrosine kinase inhibitor, in individuals with hypertension or history of cardiovascular disease and heart failure, while sunitinib may be preferred in patients with uncontrolled diabetes or oxygen-dependent COPD.

Everolimus may also be preferred in the setting of functional tumors because data indicate that everolimus delays disease progression and reduces tumor-secreted hormones from pNETs. The data for gastrin and glucagon are quite strong in this setting, notes Yao, and other data suggest that everolimus may be effective in controlling malignant hypoglycemia among patients with metastatic insulinomas.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x